A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function
Completed · Phase 1
Conditions studied: Hepatic Impairment
In brief
Study AG120-C-012 is a Phase 1, open-label, single-dose study designed to evaluate the PK, safety, and tolerability of a single 500 mg AG-120 (Ivosidenib) dose in subjects with mild or moderate hepatic impairment (HI) compared to subjects with normal hepatic function. The study will be conducted at 2 US centers.
Key facts
- Study ID
- NCT03282513
- Run by
- Agios Pharmaceuticals, Inc.
- People needed
- 33
- Starts
- 2017-09-26
- Expected to finish
- 2018-03-31
- Last updated by the study team
- 2018-04-27
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.
Where it is running
- DaVita Clinical Research- Colorado — Lakewood, Colorado, United States
- DaVita Clinical Research- Minnesota — Minneapolis, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.